Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 15Phase 4 13Phase NA 12Phase 1 4Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Breast 1

Conditions

Vomiting 1Pruritus 1Nausea 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Breast Neoplasms 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Aprepitant × Clear all
NCT06931119 2025-04-17

Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients

Rabin Medical Center

Phase 1 Not yet recruiting
30 enrolled

Pruritus

NCT00719173 2024-11-04

NRR

UNC Lineberger Comprehensive Cancer Center

Phase 1 Completed
19 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

NCT00871910 2017-10-23

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Merck Sharp & Dohme LLC

Phase 1 Completed
81 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02058277 2014-06-24

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

Pfizer

Phase 1 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡